Company news

PMV Pharmaceuticals, Inc. news in 2025

PMV Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

November 12, 2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

October 24, 2025

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

September 10, 2025

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 7, 2025

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

May 23, 2025

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

May 9, 2025

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

March 3, 2025

Decks in 2025